Analyzing Cytori Therapeutics (CYTX) and Its Competitors

Cytori Therapeutics (NASDAQ: CYTX) is one of 79 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its competitors? We will compare Cytori Therapeutics to similar businesses based on the strength of its valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and earnings.

Institutional & Insider Ownership

12.0% of Cytori Therapeutics shares are held by institutional investors. Comparatively, 64.4% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 1.9% of Cytori Therapeutics shares are held by insiders. Comparatively, 12.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Cytori Therapeutics has a beta of 2.79, suggesting that its stock price is 179% more volatile than the S&P 500. Comparatively, Cytori Therapeutics’ competitors have a beta of 0.95, suggesting that their average stock price is 5% less volatile than the S&P 500.


This table compares Cytori Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cytori Therapeutics -367.33% -228.21% -69.19%
Cytori Therapeutics Competitors -128.55% -97.82% -11.52%

Earnings & Valuation

This table compares Cytori Therapeutics and its competitors gross revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Cytori Therapeutics $4.66 million -$22.04 million -0.39
Cytori Therapeutics Competitors $975.11 million $120.37 million 214.51

Cytori Therapeutics’ competitors have higher revenue and earnings than Cytori Therapeutics. Cytori Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings for Cytori Therapeutics and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytori Therapeutics 0 1 1 0 2.50
Cytori Therapeutics Competitors 204 1192 2649 85 2.63

Cytori Therapeutics presently has a consensus target price of $3.65, suggesting a potential upside of 928.17%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 7.58%. Given Cytori Therapeutics’ higher probable upside, equities research analysts plainly believe Cytori Therapeutics is more favorable than its competitors.


Cytori Therapeutics competitors beat Cytori Therapeutics on 10 of the 12 factors compared.

About Cytori Therapeutics

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient’s own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.

Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with's FREE daily email newsletter.

Leave a Reply